Trial Profile
An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SUNPAZ
- Sponsors Novartis Pharmaceuticals
- 01 Jan 2020 Results (n=29) assessing efficacy and safety of everolimus as second-line treatment in patients with clear-cell metastatic renal-cell carcinoma (mRCC) published in the Urologia Internationalis.
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 27 May 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.